Clinical, pharmacoepidemiological and pharmacoeconomic evaluation of a long-term treatment of schizophrenia with Risset in regular psychiatric practice
The results of a comprehensive analysis of a 12-month use of risperidon generic Risset for treatment of schizophrenic patients in regular psychiatric practice suggest its clinical efficacy and cost-saving potential if compared with previous medication, predominantly with conventional antipsychotics